ICP is the pressure exerted by the cranial contents on the dural envelope and consists of the partial pressures of the brain, blood, and cerebrospinal fluid. Many conditions can increase intracranial pressure. Common causes include traumatic brain injury, stroke, brain tumor, hydrocephalus, meningitis, hemorrhage.
Elevated ICP is a serious and life-threatening condition requiring prompt identification and rapid treatment. Untreated intracranial hypertension has a 50%-60% mortality rate, while delayed treatment results in varying degrees of intellectual, physical, and neurological disabilities.
Current wired ICP monitoring systems largely involve a surgical procedure that introduces an intracranial probe through the skull which is then externalized through the scalp (the distal end of the wire is connected to a monitor). Although, over the last few decades, wired ICP monitoring has become the standard of care, the percutaneous devices have major issues of
1. Significant risks of serious, potentially life-threatening, transcutaneous infection
2. Sensor drift
3. Patient tethered to the bed/monitor
4. Prolonged hospital stay and increased healthcare expenditure
1. Wireless system eliminates transcutaneous infection risk
After surgical insertion of Reco's less invasive wireless ICP sensor, the scalp is closed with skin sutures. By removing the infection path, wireless ICP monitoring enables longer recording, which significantly increases the yield of diagnosis of abnormal ICP.
2. Wearable system enables ambulatory monitoring
Reco's smartphone-sized battery-powered reader enables ambulatory and continuous monitoring. No more tethered to bedside monitor.
3. Saving healthcare cost by reducing hospital stay and unnecessary imaging & operation
The ICP of most patients with chronic neurological diseases can be monitored at home after surgical insertion of Reco's wireless ICP sensor. Home ICP monitoring could considerably reduce hospital stay period and saving healthcare cost. The other added benefits are avoiding unnecessary diagnosis and operations, usually MRI head and shunt series.
A very warm welcome to our Quality and Regulatory Manager, Uma.
Uma has over 12 years of experience in the medical device quality, regulatory and clinical fields. Prior to joining Reco, Uma was Group Lead, Global Regulatory Affairs and Quality Assurance for medical companies in the UK, USA, and Germany. She guided her company's MDR assessment for EU previously and successfully cleared multiple class II and class III products.
Her passion and in-depth knowledge will boost our progress to regulatory approval and clinical adoption in the UK and globally.
It is our pleasure to welcome Dave to Reco Medical as a project manager.
With over thirty years' experience of delivering high-performing products to healthcare markets and creating inventive start-ups, Dave brings a wealth of invaluable knowledge and
skills to drive the project towards success.
We are delighted that we have been awarded Innovate UK Smart Grant to complete chronic animal trial and ready for first-in-human trial in 2022.
This funding would provide a transformative boost to the commercialisation of the wireless
ICP monitoring system. We will continue our innovation and keeping its leading position in market.
The paper "Wireless Interrogation of Implantable SAW Sensors" presents a system for wirelessly interrogating surface acoustic wave (SAW) sensors implanted in the main pulmonary artery (PA), where the pressure (PAP) is a very important parameter in the management of heart failure patients.
A UK patent was filed by Imperial College Innovations (application number 2003380.9), covering the core technology of wireless ICP monitoring.
This patent will be exclusively licensed to the Reco Medical.
Reco Medical was formed to commercialize wireless Intracranial Pressure monitoring system (ICP).
The technology was developed by co-founders Dr Mohammad Reza Bahmanyar, Prof. Christopher McLeod, and Dr Longfang Zou, mainly supported by the Department of Health and Social Care and the Wellcome Trust at Imperial College London. The technology attracted commercial interest and a start-up was founded by the team in 2016 with £3.5 million investment for cardiovascular applications.